Cover Image
市場調查報告書

青光眼:到2023年的流行病學的預測

EpiCast Report: Glaucoma - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 332317
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
青光眼:到2023年的流行病學的預測 EpiCast Report: Glaucoma - Epidemiology Forecast to 2023
出版日期: 2015年05月12日 內容資訊: 英文 52 Pages
簡介

青光眼是眼睛的視神經障礙產生的眼科疾病,隨著病情進行可能會失明。特別在老年人中,青光眼是失明的主要原因之一。全球主要7個國家青光眼的患病數量次10年預計以14.60%增加,從2013年的1,370萬件到2023年擴大到1,570萬。美國和日本佔整體60%。

本報告提供青光眼的概要與風險係數,及全球7個國家的趨勢,以及青光眼的流行病學的預測、患病數量趨勢彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險係數和共生病症
  • 全球的趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測方法
  • 青光眼的流行病學的預測
    • 青光眼全患病數量
    • 各年齡
    • 性別
    • 各臨床
    • NTG患病數
    • POAG及PACG已診斷的患病數量
  • 議論
    • 流行病學的預測
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考文獻
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER081-15

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), secondary glaucoma, and congenital glaucoma. Other less common types of glaucoma include normal-tension glaucoma (NTG), pseudoexfoliation glaucoma, and pigmentary glaucoma (NEI, 2014b). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for about 80-90% of all glaucoma cases (Mayo Clinic, 2014). OAG and ACG can be primary (primary open-angle glaucoma [POAG] and primary angle-closure glaucoma [PACG], respectively) or secondary, depending on the cause.

GlobalData epidemiologists forecast that the total prevalent cases of glaucoma in the 7MM will grow by 14.60% over the next decade, from 13,748,430 total prevalent cases in 2013 to 15,761,674 total prevalent cases in 2023, with almost 60% of the total prevalent cases occurring in the US and Japan together.

The increase in the number of total prevalent cases of glaucoma in the 7MM can be attributed to changing population demographics in the respective markets. However, further epidemiological research is warranted given that there is a paucity of national and international data evaluating the prevalence and trends of glaucoma worldwide. There is also a need to clearly demarcate the glaucoma population in each clinical type, as currently available epidemiological literature fails to clearly demarcate different glaucoma populations.

Scope

  • The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of total prevalent cases of glaucoma segmented by age (in five-year increments beginning at age 40), sex, clinical type (POAG, PACG, secondary glaucoma, and congenital glaucoma the total prevalent cases of NTG, which is a sub-type of OAG; and the diagnosed prevalent cases of POAG and PACG in these markets.
  • The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
  • Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
  • Identify the percentage of glaucoma prevalent cases by clinical type.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Sources Not Used
  • 3.5. Epidemiological Forecast for Glaucoma (2013-2023)
    • 3.5.1. Total Prevalent Cases of Glaucoma
    • 3.5.2. Age-Specific Total Prevalent Cases of Glaucoma
    • 3.5.3. Sex-Specific Total Prevalent Cases of Glaucoma
    • 3.5.4. Age-Standardized Total Prevalence of Glaucoma
    • 3.5.5. Total Prevalent Cases of Glaucoma, by Clinical Type
    • 3.5.6. Total Prevalent Cases of NTG
    • 3.5.7. Diagnosed Prevalent Cases of POAG and PACG
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Types of Glaucoma
  • Table 2: Risk Factors and Comorbidities for Glaucoma
  • Table 3: 7MM, Sources of Glaucoma Total Prevalence Data Used in the Epidemiology Forecast
  • Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of Glaucoma Segmented by Clinical Types
  • Table 5: 7MM, Sources Not Used in the Epidemiological Analysis of Glaucoma
  • Table 6: 7MM, Total Prevalent Cases of Glaucoma, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 7: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N (Row %), 2013
  • Table 8: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ≥40 Years, N (Row %), 2013
  • Table 9: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ≥40 Years, N (Row %), 2013
  • Table 10: 7MM, Total Prevalent Cases of NTG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 11: 7MM, Diagnosed Prevalent Cases of POAG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 12: 7MM, Diagnosed Prevalent Cases of PACG, Ages ≥40 Years, Both Sexes, N, 2013-2023

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Glaucoma, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N, 2013-2023
  • Figure 3: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ≥40 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of Glaucoma, by Sex, Ages ≥40 Years, %, 2013
  • Figure 5: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ≥40 Years, N, 2013
  • Figure 6: 7MM, Total Prevalent Cases of NTG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 7: 7MM, Diagnosed Prevalent Cases of POAG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 8: 7MM, Diagnosed Prevalent Cases of PACG, Ages ≥40 Years, Both Sexes, N, 2013-2023
Back to Top